https://orcid.org/0000-0003-4702-7481
References
- European Medicines Agency., 2012. Guideline on the investigation of drug interactions [online]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf [Accessed 22 Oct 2020].
- Hardwick, J.P., 2008. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochemical pharmacology, 75, 2263–2275.
- Houten, S.M. and Wanders, R.J., 2010. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. Journal of inherited metabolic disease, 33, 469–477.
- Jin, Y., et al., 2011. CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug metabolism and disposition, 39, 191–198.
- Katsube, T., et al., 2020. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. European journal of clinical pharmacology. Available from: https://link.springer.com/article/10.1007/s00228-020-02960-7#article-info [Accessed 22 October 2020].
- Lok, S., et al., 1994. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature, 369, 565–568.
- Michaels, S. and Wang, M.Z., 2014. The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug metabolism and disposition, 42, 1241–51.
- Rodrigues, A.D., 2008. Drug-drug interactions. 2nd ed. New York, NY: Informa Healthcare.
- Seeley, R.R., Stephens, T.D., and Tate, P., 2000. Anatomy and physiology. New York, NY: McGraw Hill.
- Szilvassy, S.J., 2006. Haematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia. Expert Opinion on Biological Therapy, 6, 983–992.
- US Food and Drug Administration., 2017. In vitro metabolism and transporter mediated drug-drug interaction studies guidance for industry. Available from: https://www.fda.gov/media/108130/download [Accessed 22 Oct 2020].
- Yamane, M., et al., 2015. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica, 45, 230–238.